Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) Sees Significant Increase in Short Interest

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 6,434 shares, an increase of 111.4% from the August 15th total of 3,043 shares. Based on an average daily trading volume, of 418 shares, the days-to-cover ratio is currently 15.4 days.

Anthera Pharmaceuticals Stock Performance

Anthera Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.00.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, trading on the OTC Markets under the symbol ANTH, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for patients suffering from serious and rare inflammatory and autoimmune diseases. The company’s research and development efforts center on both biologic and small-molecule approaches designed to modulate key pathways in immune system dysfunction. Anthera’s strategy includes advancing lead candidates through late-stage clinical trials while exploring additional indications for its pipeline assets.

The company’s most advanced asset, blisibimod, is a selective antagonist of B-cell activating factor (BAFF) that has been evaluated in clinical studies for systemic lupus erythematosus (SLE) and primary immune thrombocytopenia (ITP).